UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 222

Sortiert nach

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

British journal of cancer, 2008-02, Vol.98 (3), p.523-528

2008

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 2001-07, Vol.19 (13), p.3267-3279

2001

Volltextzugriff (PDF)

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma

Annals of oncology, 2013-04, Vol.24 (4), p.1104-1111

2013

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of the Mitochondrial-specific Rhodacyanine Dye Analog MKT 077

Clinical cancer research, 2000-01, Vol.6 (1), p.42-49

2000

Volltextzugriff (PDF)

Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model

Cancer research (Chicago, Ill.), 1999-03, Vol.59 (5), p.1049-1053

1999

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of Temozolomide and Cisplatin in Patients with Advanced Solid Malignancies

Clinical cancer research, 1999-07, Vol.5 (7), p.1629-1637

1999

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel

Journal of clinical oncology, 2001-05, Vol.19 (9), p.2493-2503

2001

Volltextzugriff (PDF)

Oral Paclitaxel and Concurrent Cyclosporin A: Targeting Clinically Relevant Systemic Exposure to Paclitaxel

Clinical cancer research, 2000-09, Vol.6 (9), p.3459-3468

2000

Volltextzugriff (PDF)

Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay

Cancer chemotherapy and pharmacology, 1999, Vol.44 (2), p.105-110

1999

Volltextzugriff (PDF)

A Phase I and Pharmacological Study of the Farnesyl Protein Transferase Inhibitor L-778,123 in Patients with Solid Malignancies

Clinical cancer research, 2001-12, Vol.7 (12), p.3894-3903

2001

Volltextzugriff (PDF)

Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344

The Journal of pharmacology and experimental therapeutics, 2016-08, Vol.358 (2), p.199

2016

Volltextzugriff (PDF)

Using cold-stored or overwintering Aceria malherbae Nuzzaci (Acarina: Eriophyiidae), a gall-forming eriophyiid mite, for infestation of field bindweed

The Southwestern entomologist, 2003-12, Vol.28 (4), p.273-280

2003

Volltextzugriff (PDF)

Abstract P5-03-03: Polo-like Kinase 1 (PLK1) inhibition synergizes with docetaxel in basal breast cancer cells

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P5-P5-03-03

2019

Volltextzugriff (PDF)

Targeting ErbB receptor signaling: A pan-ErbB approach to cancer

Molecular cancer therapeutics, 2004-10, Vol.3 (10), p.1335-1342

Britten, Carolyn D

2004

Volltextzugriff (PDF)

G2 checkpoint abrogation and checkpoint kinase-I targeting in the treatment of cancer

British journal of cancer, 2008, Vol.98 (3), p.523-528

2008

Volltextzugriff (PDF)

Abstract P4-04-11: The 8p11-p12 amplicon oncogene ASH2L regulates expression of genes involved in tumorigenic processes and response to palbociclib via promoter H3K4me3

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P4-P4-04-11

2018

Volltextzugriff (PDF)

A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors

European journal of cancer (1990), 2016-12, Vol.69, p.S21-S22

2016

Volltextzugriff (PDF)

Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin’s Lymphoma or Multiple Myeloma

Clinical pharmacokinetics, 2009-01, Vol.48 (3), p.199-209

2009

Volltextzugriff (PDF)

A Phase I Study of Pivaloyloxymethyl Butyrate, a Prodrug of the Differentiating Agent Butyric Acid, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2002-07, Vol.8 (7), p.2142-2148

2002

Volltextzugriff (PDF)

A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.3532-3532

2009

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Irofulven, a Novel Mushroom-Derived Cytotoxin, Administered for Five Consecutive Days Every Four Weeks in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 2000-12, Vol.18 (24), p.4086-4097

2000

Volltextzugriff (PDF)

Deforolimus trial 106- A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.3509-3509

2008

Volltextzugriff (PDF)

Pharmacokinetics of oral deforolimus (AP23573, MK-8669)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.14555-14555

2008

Volltextzugriff (PDF)

Open-label study to assess effect of omeprazole (O) on pharmacokinetics of bortezomib (B) in subjects with advanced solid tumors, NHL, or multiple myeloma

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.13000-13000

2007

Volltextzugriff (PDF)

First-in-human study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-00299804, a small molecule irreversible panHER inhibitor in patients with advanced cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.3599-3599

2007

Volltextzugriff (PDF)

1 – 25 von 222

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(191)
Mit Volltextzugriff
(197)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(111)
Life Sciences & Biomedicine
(84)
Humans
(64)
Biological And Medical Sciences
(54)
Female
(44)
Male
(41)
Medical Sciences
(35)
Middle Aged
(33)
Animals
(31)
Adult
(28)
Oncology
(28)
Physical Sciences
(27)
Aged
(26)
Pharmacology. Drug Treatments
(20)
Antineoplastic Agents
(19)
Fundamental And Applied Biological Sciences. Psychology
(19)
Physics
(19)
Neoplasms - Drug Therapy
(15)
Chemistry
(14)
Exact Sciences And Technology
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma

A Phase I and Pharmacokinetic Study of the Mitochondrial-specific Rhodacyanine Dye Analog MKT 077

Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model

A Phase I and Pharmacokinetic Study of Temozolomide and Cisplatin in Patients with Advanced Solid Malignancies

Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel

Oral Paclitaxel and Concurrent Cyclosporin A: Targeting Clinically Relevant Systemic Exposure to Paclitaxel

Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay

A Phase I and Pharmacological Study of the Farnesyl Protein Transferase Inhibitor L-778,123 in Patients with Solid Malignancies

Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344

Using cold-stored or overwintering Aceria malherbae Nuzzaci (Acarina: Eriophyiidae), a gall-forming eriophyiid mite, for infestation of field bindweed

Abstract P5-03-03: Polo-like Kinase 1 (PLK1) inhibition synergizes with docetaxel in basal breast cancer cells

Targeting ErbB receptor signaling: A pan-ErbB approach to cancer

G2 checkpoint abrogation and checkpoint kinase-I targeting in the treatment of cancer

Abstract P4-04-11: The 8p11-p12 amplicon oncogene ASH2L regulates expression of genes involved in tumorigenic processes and response to palbociclib via promoter H3K4me3

A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors

Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin’s Lymphoma or Multiple Myeloma

A Phase I Study of Pivaloyloxymethyl Butyrate, a Prodrug of the Differentiating Agent Butyric Acid, in Patients with Advanced Solid Malignancies

A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies

Phase I and Pharmacokinetic Study of Irofulven, a Novel Mushroom-Derived Cytotoxin, Administered for Five Consecutive Days Every Four Weeks in Patients With Advanced Solid Malignancies

Deforolimus trial 106- A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669)

Pharmacokinetics of oral deforolimus (AP23573, MK-8669)

Open-label study to assess effect of omeprazole (O) on pharmacokinetics of bortezomib (B) in subjects with advanced solid tumors, NHL, or multiple myeloma

First-in-human study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-00299804, a small molecule irreversible panHER inhibitor in patients with advanced cancer

Suchergebnisse filtern